Delivered-To: pgepnewsletter@gmail.com
Received: by 2002:a98:c004:0:b0:1eb:e128:bbe3 with SMTP id l4csp2989654eic;
        Sat, 13 Jan 2024 15:56:16 -0800 (PST)
X-Google-Smtp-Source: AGHT+IFw/NxtdYV6sntS12gcMhZIJUb4c8PXhlDbQZ9wZFlGzhFEW0ThYLhQg25olrV3hjOKv/jd
X-Received: by 2002:a05:622a:107:b0:429:c715:1b2 with SMTP id u7-20020a05622a010700b00429c71501b2mr3874246qtw.135.1705190175988;
        Sat, 13 Jan 2024 15:56:15 -0800 (PST)
ARC-Seal: i=1; a=rsa-sha256; t=1705190175; cv=none;
        d=google.com; s=arc-20160816;
        b=t5YwEo3dSc/Zz/ohloMvlGzhuMTpdE1mkp7utkIc59lue8sHGfSw5Q8Lota+t9tuvn
         GiR3ZqWWCHfP+060FlhJXZykrjYa7CFVQXDRkkOc08PUQnqLpvyvoK1TnN+MuLbExozN
         DSFHP/kpbFQBvJXpE0LlVPX48muh8zF7ANGSCf1h7/+iZYfixPMY4Xr70TwahrQGkbcO
         Wbrq3tfdAy46MigixxAGw2Oij0HaFOveO939zX3wEt5RTvjHc9rfo3DbJC9PpTGFbQIV
         VhaY6lMxhGPK7TqZZ/Y/nBn44F938B+zTwKlwo4wGFF66UtyA3vLEz8c0R9t1vlrOOOk
         vq9Q==
ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20160816;
        h=list-unsubscribe:to:reply-to:subject:message-id:mime-version:from
         :date:dkim-signature:dkim-signature;
        bh=FuUmXkJJUCBw8tTvFoPY09J2g9BJkNLZ41DdZDhNsII=;
        fh=m8+yFGL9AGrkSifADXzxzWHypeMVd9MF7/kbikeN2H4=;
        b=F/JanQPoRxRBV3tKWlRdwDh2pSRu9DuEsopyGd5vfxvbHspcMDI+VzYL/hgfC9QkZn
         4SCkxwybNhRuaBjP9TuNpA++bS02K+zlkcEzHlx2kRcIQEX53jJ2eqjCiLpWbUV5mGKS
         kq/QZlT81xTfpwWYpBkG6pDu4qpU/Kk6PxuNgPxAWwsRqAzLdsXi9XTwbOG9PsOVaIvN
         O9j9+OysrWJ3wloBIcaBHWMXP2G1ZevJFfQZeOkTEzhGgUdv3fc6KmFtxr4YtQp5iRjO
         T6MgCScPaZ+owIstnVBARB2npqUgcyZVmeBhUJujbyWAmxKppKCqfRfohRMzHIo0FrH8
         L2qw==
ARC-Authentication-Results: i=1; mx.google.com;
       dkim=pass header.i=@isid.org header.s=s1 header.b="yZNGoO4/";
       dkim=pass header.i=@sendgrid.info header.s=smtpapi header.b=N+bcmV5e;
       spf=pass (google.com: domain of bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org designates 167.89.81.226 as permitted sender) smtp.mailfrom="bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org";
       dmarc=pass (p=NONE sp=NONE dis=NONE) header.from=isid.org
Return-Path: <bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org>
Received: from xtrwrkzn.outbound-mail.sendgrid.net (xtrwrkzn.outbound-mail.sendgrid.net. [167.89.81.226])
        by mx.google.com with ESMTPS id c13-20020ac87dcd000000b00429d58393acsi2610276qte.404.2024.01.13.15.56.15
        for <pgepnewsletter@gmail.com>
        (version=TLS1_3 cipher=TLS_AES_128_GCM_SHA256 bits=128/128);
        Sat, 13 Jan 2024 15:56:15 -0800 (PST)
Received-SPF: pass (google.com: domain of bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org designates 167.89.81.226 as permitted sender) client-ip=167.89.81.226;
Authentication-Results: mx.google.com;
       dkim=pass header.i=@isid.org header.s=s1 header.b="yZNGoO4/";
       dkim=pass header.i=@sendgrid.info header.s=smtpapi header.b=N+bcmV5e;
       spf=pass (google.com: domain of bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org designates 167.89.81.226 as permitted sender) smtp.mailfrom="bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org";
       dmarc=pass (p=NONE sp=NONE dis=NONE) header.from=isid.org
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=isid.org;
	h=content-type:from:mime-version:subject:reply-to:x-feedback-id:to:
	list-unsubscribe:cc:content-type:from:subject:to;
	s=s1; bh=FuUmXkJJUCBw8tTvFoPY09J2g9BJkNLZ41DdZDhNsII=;
	b=yZNGoO4/D+Ow2onLvajaWcOO358d0RWY7MqTkIk0hVo0cG65+/jtO/4Rwlt6/xQRlfMV
	9Da9Bp9Q/m4daf24RJ9RbFBl7nm/Lh3ue6mdgFPRrF5XPyyNPNmvM/9GxURvOMWGC8gJF2
	0s2r7UYzKtBXbtTUbpPYoLASiKxGfFJerPoB5i8f5PZ9KkPxNX+2qPavhdI5Vdj/GvT2jP
	GMEM+Kow6SkM+Knj+6l1UGToCatNC1oLcufLlh6WygWUHtw2hvYsbt8NpmMwEBJ7GlyGK/
	rUPOHmC7f7diS2aAC1KAxpxVSCxFnHoKah8gAAIEgfRvRZpw6pl7t0CuMhuM90kg==
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=sendgrid.info;
	h=content-type:from:mime-version:subject:reply-to:x-feedback-id:to:
	list-unsubscribe:cc:content-type:from:subject:to;
	s=smtpapi; bh=FuUmXkJJUCBw8tTvFoPY09J2g9BJkNLZ41DdZDhNsII=;
	b=N+bcmV5eNjFutKQ3O65eWFta0zPqz/pzrDEzULPxNdFTR9JOjQ78vQ91gYCGiSYQmt6C
	B2T3zDgNrz6qC0laDBhP8ITln4Suva7V8q8RN+6Kf1OOc9Vq3Ft4AoI/J+MJB7BmFNFgOZ
	JdWh2BxqXL9bRZyl4szCzTV4yzm3UB3n0=
Received: by filterdrecv-canary-8494898689-mtmgw with SMTP id filterdrecv-canary-8494898689-mtmgw-1-65A3231E-20
        2024-01-13 23:56:14.644460488 +0000 UTC m=+7622115.184593631
Received: from MTkyNjg2NjI (unknown)
	by geopod-ismtpd-17 (SG) with HTTP
	id M2wlZ4c2TaaUlrI4spXDfQ
	Sat, 13 Jan 2024 23:56:14.467 +0000 (UTC)
Content-Type: multipart/alternative; boundary=1ad4fd14739de34d3cef0ba0f1aeaebf67d94dbdc9e6c3c493a752bf17f3
Date: Sat, 13 Jan 2024 23:56:14 +0000 (UTC)
From: ProMED <promed@isid.org>
Mime-Version: 1.0
Message-ID: <M2wlZ4c2TaaUlrI4spXDfQ@geopod-ismtpd-17>
Subject: PRO/AH/EDR> Trichophyton indotineae - South Africa: (NL) resistance,
 1st rep
Reply-To: noreply@isid.org
X-Feedback-ID: 19268662:SG
X-SG-EID: 
 =?us-ascii?Q?lYKUi1ucKQwcfoVB1xAcbBSlsJP9QSi7ed2VWI0p5NjpCc5BQK+kujBGGO1mU1?=
 =?us-ascii?Q?iB2gK2X=2F5iYSgw92Q5nRRY9nzi4pUCMNWJrUjI6?=
 =?us-ascii?Q?Ix4Ri2=2FIOuqIcjzmq+msUfh5gG=2Fuv2Fsr4oZorx?=
 =?us-ascii?Q?DmwrPbaVRhAinZiDXcJ7bBj7ScPlm+CQsyxTCp+?=
 =?us-ascii?Q?qUANLjz2GcDzu5nnf90g7kAh0Kz3ZbBEdLvlt6Y?=
 =?us-ascii?Q?WUqoh+4sbabXBQnrHsUjiNs4pb6FhK4Bsb5apd?=
X-SG-ID: 
 =?us-ascii?Q?se=2F49CGmbS0sfR97ImeXvNhg9p9jggtUUChgqoY2wUiShGf=2FO8XJWpH34Od4Nd?=
 =?us-ascii?Q?fxXa6jil96uRcJkF+N+LeVnO1tx80ddOyoyOo=2Fc?=
 =?us-ascii?Q?Brxcl3ERAm0cOY743=2FFH59DWiSf5OzXORh1DLKt?=
 =?us-ascii?Q?hb1NMKty3PsA5ju0ZzxCrq1WQuZSEQf=2FJlWtgqv?=
 =?us-ascii?Q?cZmsyCHlNUZsDTzEazP+XQhtBA=2F4lTi+oA0rT+9?=
 =?us-ascii?Q?q3iVxIvW0ncXQuyGB4=2F8vjesX2cuD5U5oO3KXAo?=
 =?us-ascii?Q?gYpySvlZIv6gq8qgG6T9NXsu=2Fhj8NgAEugUrON=2F?=
 =?us-ascii?Q?zP4wL2PEKhPg8uJkHrCnZRSTwdmHejkfrXV26Dy?=
 =?us-ascii?Q?U=2F3r265JDnHrpx20eEi13NiG=2FhomN9qyoohwZaV?=
 =?us-ascii?Q?sPtzoNS1wUtW+UfOEwRXcV6T5mQEtBdRo5OGaMu?=
 =?us-ascii?Q?6FvPiHtRGeeVCpBbJP3CdEOVb0ZXFTZRfZorb2D?=
 =?us-ascii?Q?SDAE5wRxikqvZjkzCel1un2N8GfFVdGBAPLAzt3?=
 =?us-ascii?Q?IyJGhWuQWMseDoytleoSvwx4e99y4DUVlej1Q4E?=
 =?us-ascii?Q?0KaGMWSoo2qvJ=2F9CWQxbrVUnL3vMgQYBRznHAht?=
 =?us-ascii?Q?ZPLOoCMUefyIgy5bqnvt54HaGJtAG5oEwFIvhig?=
 =?us-ascii?Q?jQFKqmgURXrb+l9R1XTy6n5WKvP9p8=2FP7WJoq0B?=
 =?us-ascii?Q?LU0QUch9BDQvNxPMZyVe9WHw0ENFunj4h8aIft7?=
 =?us-ascii?Q?Ny8ovaRertY3kEVueY=2FUU2iTSW9VJ4IcxIu0fst?=
 =?us-ascii?Q?nFp=2Fb3OKIV=2Fr907wC36QQCjLzdt+ie8LceQCeEp?=
 =?us-ascii?Q?qApwX6UR0qr9tCmdoAgAhaq0rQ=3D=3D?=
To: pgepnewsletter@gmail.com
X-Entity-ID: 3CKJgmVGbBVD214dsRqreg==
List-Unsubscribe: 
 =?us-ascii?Q?=3Cmailto=3Aunsubscribe=40em7004=2Eisid=2Eorg=3Fsubject=3D19268662=2E3C0v7McI4?=
 =?us-ascii?Q?pZkOp9fiblW3q9iAxAf5OCYmK5SjcEdRxxoMDAw?=
 =?us-ascii?Q?dTAwMKIJpnY9MxpHw6-kd2ZyBjZprXUZdEixinw?=
 =?us-ascii?Q?9hys5nAPNzmh-jarXwLSJrQe-iFAxVji-KGxUqN?=
 =?us-ascii?Q?sMKCAf6jnofvD00jxtbryF3L1AApeQkZR8UIs56?=
 =?us-ascii?Q?2Qpq2qbx4nv6s=5F4Uw=3D=3D=2EfoLHL-UxBRHPdHiYiTJ?=
 =?us-ascii?Q?u=5FUk9o3Xsma1=5FkG1DpZNapftoMDAwdTAwMLFcPj?=
 =?us-ascii?Q?GadiNHZ=5FjocHwCCdGT8lhNf8HiJmfYS27NjVBSh?=
 =?us-ascii?Q?=5Ffb=5F1MjhfCUdfB1TgbhILBWj59aoco9cZ-bj0Id?=
 =?us-ascii?Q?n0=5FD0v2OXWzFK56DE994rARItL6dyptInMR3=5FKj?=
 =?us-ascii?Q?0w21oItUURncLv3HKUXzi2HiNAcOOoykiX-=5FByb?=
 =?us-ascii?Q?IjVx0hsbsPOywTqN7rbixnKnJnCgnqaU9xsWV=5Fk?=
 =?us-ascii?Q?TD1PkACXno5S0DGoCcTttnrSw2O8qUA7lwuT2xG?=
 =?us-ascii?Q?KswjdTnoCwug9nwDs-DPiOrBxvFoWihmbJ4uYoL?=
 =?us-ascii?Q?1LNxbNx=5FJvE1ePI2Pfe3avg2PP7TexMqdL-6e=5F9?=
 =?us-ascii?Q?zSeGbJzTuD2wUo=5FoJ86lAWdYuNfXI2YTp93Ddpc?=
 =?us-ascii?Q?XYHOxHop822=5FSVkfDwL2CGx0jjqDPzwvl2Y0L4I?=
 =?us-ascii?Q?9MQNkNS6zRoxRrm-ocsLeS2RX64sTIO08zYNUhD?=
 =?us-ascii?Q?uF27sTtItI-EVx6bJoJDEw3DSNpQQjw=5FrEKrM93?=
 =?us-ascii?Q?Jg6oPzDiK-JxSPE2rQAPg-hNLdCwXZm-ePIrknt?=
 =?us-ascii?Q?KhzppcRZs6CZOq7WBi-a9bnN0GffdIaxPB8QyHW?=
 =?us-ascii?Q?5OStIZVeG0cywvnK1ikC=5FLvBiWtrDoxXgQtqECl?=
 =?us-ascii?Q?=5F2G2PS6oTWD-lFIwJLMGtLkzSZEOEWpEbgARbsL?=
 =?us-ascii?Q?K9Pj82Jc-ik9bfBvoFMK68Zx-ETC0E3vrazfyfn?=
 =?us-ascii?Q?V1aswJoIxHOYoyZZtHfEsxPER7TK9ZxR9ucH1fs?=
 =?us-ascii?Q?CKkjEb0pbI4qiO1Txnfj9DVre8CfdHVONNbSgQU?=
 =?us-ascii?Q?8rIsWad7RfIKxN3005CBE0k780hk=5FG=5Fsq-0RgqU?=
 =?us-ascii?Q?eMbKFDj8SAqOspjUipJ3K5h5ADyiipOdywP75tX?=
 =?us-ascii?Q?vTnCl8Hp8FHNXeLPpRMyaZq9ahAcvggp3FPUvOw?=
 =?us-ascii?Q?7zuNAGQ6pSsSCtDyDiGoKGhmWQ83tGG-2kDT=5Fcz?=
 =?us-ascii?Q?b90UAOvCYoIha1f752W9pex92DlSeRKe=5FI5zBXt?=
 =?us-ascii?Q?yota8ypaXoYw9Zuj2wd1J21TT-CQneXvq0qAy=5Fu?=
 =?us-ascii?Q?NK2ep5O35P9ZHxQCl2mEWUSuVfl9llpPPc=5FLwxx?=
 =?us-ascii?Q?1cO6XiFKgb2sa5H5aINpubmoQRk=3D=3E?=

--1ad4fd14739de34d3cef0ba0f1aeaebf67d94dbdc9e6c3c493a752bf17f3
Content-Transfer-Encoding: quoted-printable
Content-Type: text/plain; charset=us-ascii
Mime-Version: 1.0

TRICHOPHYTON INDOTINEAE - SOUTH AFRICA: (KWAZULU-NATAL) RESISTANCE,
FIRST REPORT
***************************************************************************=
*****
A ProMED-mail post
<http://www.promedmail.org>
ProMED-mail is a program of the
International Society for Infectious Diseases
<http://www.isid.org>

Date: Wed 10 Jan 2024
Source: Medical Brief [edited]
<https://www.medicalbrief.co.za/first-in-africa-antifungal-resistant-ringwo=
rm-detected-in-kzn/>


A first confirmed case of antifungal-resistant ringworm has been
recorded in KwaZulu-Natal, the National Institute for Communicable
Diseases (NICD) confirmed, saying 2 people were being treated for the
condition.

_Trichophyton indotineae_ is the first infection of its kind in
Africa, reports News24, with the NICD confirming the positive
diagnosis a week before Christmas [2023], reporting it in the Public
Health Surveillance Bulletin. Also known as _Trichophyton
mentagrophytes_ type VIII, it is described as an antifungal-resistant
fungus resulting in extensive disfiguring and difficult-to-treat
ringworm infections.

The head of the Centre for Healthcare-Associated Infections,
Antimicrobial Resistance and Mycoses, Professor Nalesh Govender, said
the true number of antifungal-resistant ringworm cases was difficult
to estimate, "because testing to determine whether antifungal
medicines can effectively treat a ringworm is not widely available."
He added that this was first confirmed case of the _Trichophyton
indotineae_ ringworm infection on the continent, and reasons for the
condition could include:
- Overuse of over-the-counter topical antifungal creams;
- Inappropriate use of potent topical steroid creams by people with
rashes;
- Inappropriate prescription of antifungal medicines;
- Global travel and migration from regions where the
antifungal-resistant infections are more common.

The KwaZulu-Natal Department of Health said it was unaware of the
antifungal-resistant infection.

--
Communicated by:
ProMED
via
ProMED-EAFR

[The confirmation of the first case of antifungal-resistant ringworm
caused by _Trichophyton indotineae_ in KwaZulu-Natal raises
significant concerns about the potential spread and impact of this
resistant fungus in Africa. The disfiguring nature and difficulty in
treating these ringworm infections underscore the urgent need for
proactive measures.

The identified factors contributing to this condition, such as overuse
of over-the-counter antifungal creams, inappropriate application of
potent topical steroids, and global travel, emphasize the importance
of education and awareness campaigns to guide proper medication usage.
Moreover, it is crucial to enhance diagnostic capabilities to
accurately identify and differentiate antifungal-resistant ringworm
cases.

The KwaZulu-Natal Department of Health should collaborate with
healthcare professionals to establish protocols for testing and
reporting such cases promptly. Strengthening surveillance systems and
sharing information across healthcare networks can aid in
understanding the true prevalence of _Trichophyton indotineae_
infections.

Given the challenging nature of these infections, medical
practitioners must be vigilant in identifying symptoms. Symptoms of
_Trichophyton indotineae_ ringworm may include persistent and
worsening skin rashes; patients typically present with large or
widespread annular, scaly, erythematous pruritic plaques.

Public health initiatives should focus on promoting responsible use of
antifungal medications, discouraging self-diagnosis, and encouraging
individuals with persistent skin issues to seek professional medical
advice. - Mod.TU

ProMED map:
KwaZulu-Natal, South Africa:
<https://promedmail.org/promed-post?place=3D8714216,67881>]

[See Also:
2023
----
Trichophyton indotineae - USA: (NYC) drug-resistant, 1st rep
http://promedmail.org/post/20230512.8709998]
.................................................tu/rd/ya/rd/jh
*##########################################################*
************************************************************
ProMED makes every effort to verify the reports that are posted, but the ac=
curacy
and completeness of the information, and of any statements or opinions base=
d
thereon, are not guaranteed. The reader assumes all risks in using informat=
ion
posted or archived by ProMED. ISID and its associated service providers sha=
ll not
be held responsible for errors or omissions or held liable for any damages =
incurred
as a result of use or reliance upon posted or archived material.
************************************************************
Donate to ProMED. Details available at: https://isid.networkforgood.com/pro=
jects/79924-invest-in-the-mission.
************************************************************
Visit ProMED's website at https://www.promedmail.org/.
Submit all items for posting via the ProMED website at https://promedmail.o=
rg/submitinfo/.
If you have any questions or need support, please contact us via the ProMED=
 website at  https://promedmail.org/support/.
You may subscribe/unsubscribe at  https://isid.org/promedmail-subscribe/.
Unsubscribe Preferences ( https://u19268662.ct.sendgrid.net/asm/?user_id=3D=
19268662&data=3D_Gn-pwZHESOMEGyuslEVbI-d0ocH4IwLiqKY5JOVEhloMDAwdTAwMDXdJJT=
xAIbI4R-vayurVbwqMCEwBJdGIzKhW2GGrlC1XqHcarlk5JQ6IKtwaFlp327tdwnsjsuFkiTzIQ=
1L6FRFNVC1z98og2lx0gKZnLM3xgDx8_JxAFm4Zsz_LyXrVhwkXFerTvv1-nmvIyUT21_MBn18S=
lld2BtmTn51ugUgwevTOPA6W4kEIIk9iSqmAodJvVM2ZeEox1IefcvDKecdYGTNWDI_h8MMABe8=
hP84RtsmuHqixf3Y0IlV3onB2ArimI_lAOrgoamDxuioZWrf4_yYMXlPesopF5iQMqjwrscH_AZ=
6RJM7OztP4gAWsYqnCvxe56BS0XcKH9Zm6QlIX9q9Vvz-pNZcWFtpryOoibW4Qs8w48AlvYdGsT=
QRPKBTHkuGo6uqoaFXqkng6tbEVQt8LRk6WKuC_YI94Hlxc-KQMW3Bm8NzdUMg5j1Pl_gEKMFMA=
GNYaGHrdD3otJLOooIpSCXI1qamZfY3ilIuUwdkiHpwF2cXKdzwgNY-omdDQM3HDy_iVeO2Al6r=
GLCxejJcm72V3z8pJ-FA2X9R9kOfM-FDCdNirIPmK9w4y03qsL8VsybUZWl-g5Lh5xnZj77Vgca=
4f8c4JKQpPRKm9g9OJXN6M-gzS5V-KGQstZGCDyk6ut4m2hK8d77oUEPTFoZhll6w_j9Y6g0peD=
g6e6RtlcrWxIzPR-6uJ-8K7Y3c3TSJM7oqfhfaPEH2YhCpzS0p05SfE9qxNSj8PpEr5b6IQrQJP=
MrqXON5K1ZJilY1FcksnGELEFjqeKK1_xh7I3Z9xKsjQBQW12MNpYQ2XC3Hl7GWIHy7xEhemLf2=
3fZ5x63S0GELIA34YahZezo-bd6qDi7A68eu7I1yqRoYbWhJSTbobWb6W-OmM6Beze5u8nymUrr=
0Kl-4nFvxdXSM0MFF_a_DEX2wZgNDnYClvUHfmPk2WsFpu5sBpyrHBVDX79OPC7ZBpCZuf4ZBs4=
3W2ko9sRq5LazbMIiKTSZLyZnHdgnl-GXBRsdbFYqi63wfp4ax_DPO__sgrco4u1EjoTEcyQ7UR=
to1G65HC-tazjoORRB8g_H9l5NCTHEQFJnGqZcZE9b_hlXDa3wBKep_AzQtTumZtogUDfmeU6MD=
bGSkKFd7LvF2K70g9SkJiI1ydpYmLSXbL1Hxz21sls3FM-q3L6Fpp6qJwrQF7Qee )
############################################################
############################################################

--1ad4fd14739de34d3cef0ba0f1aeaebf67d94dbdc9e6c3c493a752bf17f3
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset=us-ascii
Mime-Version: 1.0

<!DOCTYPE HTML>
<html>
<head>
<meta http-equiv=3D"Content-Type" content=3D"text/html; charset=3DUTF-8" />
</head>
<body>TRICHOPHYTON INDOTINEAE - SOUTH AFRICA: (KWAZULU-NATAL) RESISTANCE,<b=
r>FIRST REPORT<br>*********************************************************=
***********************<br>A ProMED-mail post<br><a href=3D"https://u192686=
62.ct.sendgrid.net/ss/c/wscE2ng5fl6JrPIt48tisIijpefK5PNjW-mL-YZGnfgDOxU1G3g=
jwnPSi2Tfv3HA/42y/nKCMvZhtTzCh12oYB-L6QA/h0/CHGC1hlK3xhl5Y6E8Q7Nx7aYzeeozHN=
E3cPVRFTrP8c">http://www.promedmail.org</a><br>ProMED-mail is a program of =
the<br>International Society for Infectious Diseases<br><a href=3D"https://=
u19268662.ct.sendgrid.net/ss/c/wscE2ng5fl6JrPIt48tisCT5tpD4Upm3qyMCbcYSQvc/=
42y/nKCMvZhtTzCh12oYB-L6QA/h1/nmZX3iBeDDv--WTvOK3XqyM5YpPcsfPvKC4LUHe01Jg">=
http://www.isid.org</a><br><br>Date: Wed 10 Jan 2024=0D<br>Source: Medical =
Brief [edited]=0D<br><a href=3D"https://u19268662.ct.sendgrid.net/ss/c/TLh_=
csrC34X_iXpbYoMam-AdbplO2c-RuvAEfcVDhP7ocFx88Tfbt5rRqPrl2FIPlhe65HbYONUJJRX=
-F0Aay92UM-dUcSFpCEjHd4JTJKotirVLhuUhIN09UH1hm7SRVNm1wpAidNSvXc0XmWua2A/42y=
/nKCMvZhtTzCh12oYB-L6QA/h2/RtSRHaKkpX3wlguQo1C6_Q6MQvVMg7BZpC8OiRnGWPg">htt=
ps://www.medicalbrief.co.za/first-in-africa-antifungal-resistant-ringworm-d=
etected-in-kzn/</a>=0D<br>=0D<br>=0D<br>A first confirmed case of antifunga=
l-resistant ringworm has been<br>recorded in KwaZulu-Natal, the National In=
stitute for Communicable<br>Diseases (NICD) confirmed, saying 2 people were=
 being treated for the<br>condition.=0D<br>=0D<br>_Trichophyton indotineae_=
 is the first infection of its kind in<br>Africa, reports News24, with the =
NICD confirming the positive<br>diagnosis a week before Christmas [2023], r=
eporting it in the Public<br>Health Surveillance Bulletin. Also known as _T=
richophyton<br>mentagrophytes_ type VIII, it is described as an antifungal-=
resistant<br>fungus resulting in extensive disfiguring and difficult-to-tre=
at<br>ringworm infections.=0D<br>=0D<br>The head of the Centre for Healthca=
re-Associated Infections,<br>Antimicrobial Resistance and Mycoses, Professo=
r Nalesh Govender, said<br>the true number of antifungal-resistant ringworm=
 cases was difficult<br>to estimate, "because testing to determine whether =
antifungal<br>medicines can effectively treat a ringworm is not widely avai=
lable."<br>He added that this was first confirmed case of the _Trichophyton=
<br>indotineae_ ringworm infection on the continent, and reasons for the<br=
>condition could include:=0D<br>- Overuse of over-the-counter topical antif=
ungal creams;=0D<br>- Inappropriate use of potent topical steroid creams by=
 people with<br>rashes;=0D<br>- Inappropriate prescription of antifungal me=
dicines;=0D<br>- Global travel and migration from regions where the<br>anti=
fungal-resistant infections are more common.=0D<br>=0D<br>The KwaZulu-Natal=
 Department of Health said it was unaware of the<br>antifungal-resistant in=
fection.=0D<br>=0D<br>--=0D<br>Communicated by:=0D<br>ProMED=0D<br>via=0D<b=
r>ProMED-EAFR<br><br>[The confirmation of the first case of antifungal-resi=
stant ringworm<br>caused by _Trichophyton indotineae_ in KwaZulu-Natal rais=
es<br>significant concerns about the potential spread and impact of this<br=
>resistant fungus in Africa. The disfiguring nature and difficulty in<br>tr=
eating these ringworm infections underscore the urgent need for<br>proactiv=
e measures.=0D<br>=0D<br>The identified factors contributing to this condit=
ion, such as overuse<br>of over-the-counter antifungal creams, inappropriat=
e application of<br>potent topical steroids, and global travel, emphasize t=
he importance<br>of education and awareness campaigns to guide proper medic=
ation usage.<br>Moreover, it is crucial to enhance diagnostic capabilities =
to<br>accurately identify and differentiate antifungal-resistant ringworm<b=
r>cases.=0D<br>=0D<br>The KwaZulu-Natal Department of Health should collabo=
rate with<br>healthcare professionals to establish protocols for testing an=
d<br>reporting such cases promptly. Strengthening surveillance systems and<=
br>sharing information across healthcare networks can aid in<br>understandi=
ng the true prevalence of _Trichophyton indotineae_<br>infections.=0D<br>=0D=
<br>Given the challenging nature of these infections, medical<br>practition=
ers must be vigilant in identifying symptoms. Symptoms of<br>_Trichophyton =
indotineae_ ringworm may include persistent and<br>worsening skin rashes; p=
atients typically present with large or<br>widespread annular, scaly, eryth=
ematous pruritic plaques.=0D<br>=0D<br>Public health initiatives should foc=
us on promoting responsible use of<br>antifungal medications, discouraging =
self-diagnosis, and encouraging<br>individuals with persistent skin issues =
to seek professional medical<br>advice. - Mod.TU<br><br>ProMED map:<br>KwaZ=
ulu-Natal, South Africa:<br><a href=3D"https://u19268662.ct.sendgrid.net/ss=
/c/sSnCkKCWBvais3EuVAOvgy2WOIX7pp1nXnn4AbwuQ3Z6WbkfhqXYXU-aTMPJ8yThPhUh-f5K=
7qLYERVqdzEBcA/42y/nKCMvZhtTzCh12oYB-L6QA/h3/GTVBrQBBmzvBldydDf7-cJL-yp9L8y=
l41EZ1H5A8dss">https://promedmail.org/promed-post?place=3D8714216,67881</a>=
]<br><br>[See Also:<br>2023=0D<br>----=0D<br>Trichophyton indotineae - USA:=
 (NYC) drug-resistant, 1st rep<br>http://promedmail.org/post/20230512.87099=
98]<br>.................................................tu/rd/ya/rd/jh<br><=
/body>
</html><!DOCTYPE HTML>
<html>
<head>
<meta http-equiv=3D"Content-Type" content=3D"text/html; charset=3DUTF-8" />
</head>
<body>*##########################################################*<br>*****=
*******************************************************<br>ProMED makes eve=
ry effort to verify the reports that are posted, but the accuracy<br>and co=
mpleteness of the information, and of any statements or opinions based<br>t=
hereon, are not guaranteed. The reader assumes all risks in using informati=
on<br>posted or archived by ProMED. ISID and its associated service provide=
rs shall not<br>be held responsible for errors or omissions or held liable =
for any damages incurred<br>as a result of use or reliance upon posted or a=
rchived material.<br>******************************************************=
******<br>Donate to ProMED. Details available at: https://isid.networkforgo=
od.com/projects/79924-invest-in-the-mission.<br>***************************=
*********************************<br>Visit ProMED's website at https://www.=
promedmail.org/.<br>Submit all items for posting via the ProMED website at =
https://promedmail.org/submitinfo/.<br>If you have any questions or need su=
pport, please contact us via the ProMED website at  https://promedmail.org/=
support/.<br>You may subscribe/unsubscribe at  https://isid.org/promedmail-=
subscribe/.<br><div><a href=3D"https://u19268662.ct.sendgrid.net/asm/?user_=
id=3D19268662&amp;data=3D_Gn-pwZHESOMEGyuslEVbI-d0ocH4IwLiqKY5JOVEhloMDAwdT=
AwMDXdJJTxAIbI4R-vayurVbwqMCEwBJdGIzKhW2GGrlC1XqHcarlk5JQ6IKtwaFlp327tdwnsj=
suFkiTzIQ1L6FRFNVC1z98og2lx0gKZnLM3xgDx8_JxAFm4Zsz_LyXrVhwkXFerTvv1-nmvIyUT=
21_MBn18Slld2BtmTn51ugUgwevTOPA6W4kEIIk9iSqmAodJvVM2ZeEox1IefcvDKecdYGTNWDI=
_h8MMABe8hP84RtsmuHqixf3Y0IlV3onB2ArimI_lAOrgoamDxuioZWrf4_yYMXlPesopF5iQMq=
jwrscH_AZ6RJM7OztP4gAWsYqnCvxe56BS0XcKH9Zm6QlIX9q9Vvz-pNZcWFtpryOoibW4Qs8w4=
8AlvYdGsTQRPKBTHkuGo6uqoaFXqkng6tbEVQt8LRk6WKuC_YI94Hlxc-KQMW3Bm8NzdUMg5j1P=
l_gEKMFMAGNYaGHrdD3otJLOooIpSCXI1qamZfY3ilIuUwdkiHpwF2cXKdzwgNY-omdDQM3HDy_=
iVeO2Al6rGLCxejJcm72V3z8pJ-FA2X9R9kOfM-FDCdNirIPmK9w4y03qsL8VsybUZWl-g5Lh5x=
nZj77Vgca4f8c4JKQpPRKm9g9OJXN6M-gzS5V-KGQstZGCDyk6ut4m2hK8d77oUEPTFoZhll6w_=
j9Y6g0peDg6e6RtlcrWxIzPR-6uJ-8K7Y3c3TSJM7oqfhfaPEH2YhCpzS0p05SfE9qxNSj8PpEr=
5b6IQrQJPMrqXON5K1ZJilY1FcksnGELEFjqeKK1_xh7I3Z9xKsjQBQW12MNpYQ2XC3Hl7GWIHy=
7xEhemLf23fZ5x63S0GELIA34YahZezo-bd6qDi7A68eu7I1yqRoYbWhJSTbobWb6W-OmM6Beze=
5u8nymUrr0Kl-4nFvxdXSM0MFF_a_DEX2wZgNDnYClvUHfmPk2WsFpu5sBpyrHBVDX79OPC7ZBp=
CZuf4ZBs43W2ko9sRq5LazbMIiKTSZLyZnHdgnl-GXBRsdbFYqi63wfp4ax_DPO__sgrco4u1Ej=
oTEcyQ7URto1G65HC-tazjoORRB8g_H9l5NCTHEQFJnGqZcZE9b_hlXDa3wBKep_AzQtTumZtog=
UDfmeU6MDbGSkKFd7LvF2K70g9SkJiI1ydpYmLSXbL1Hxz21sls3FM-q3L6Fpp6qJwrQF7Qee" =
target=3D"_blank" class=3D"Unsubscribe--unsubscribePreferences" style=3D"fo=
nt-family:sans-serif;text-decoration:none;">Unsubscribe Preferences</a></di=
v><br>############################################################<br>#####=
#######################################################<br><br><img src=3D"=
https://u19268662.ct.sendgrid.net/ss/o/LbtalBvHhFtzyiegKfBhew/42y/nKCMvZhtT=
zCh12oYB-L6QA/ho.gif" alt=3D"" width=3D"1" height=3D"1" border=3D"0" style=
=3D"height:1px !important;width:1px !important;border-width:0 !important;ma=
rgin-top:0 !important;margin-bottom:0 !important;margin-right:0 !important;=
margin-left:0 !important;padding-top:0 !important;padding-bottom:0 !importa=
nt;padding-right:0 !important;padding-left:0 !important;"/></body>
</html>
--1ad4fd14739de34d3cef0ba0f1aeaebf67d94dbdc9e6c3c493a752bf17f3--
